Introduction
============

Congenital hypothyroidism (CH) is the most common pediatric endocrinological disorder and an important cause of preventable mental retardation \[[@b1-apem-2018-23-4-169]\]. After the introduction of neonatal screening for CH, the incidence was 1 case per 3,684 live births \[[@b2-apem-2018-23-4-169]\], but the incidence has increased to 1 case per 1,000--2,000 live births of late \[[@b3-apem-2018-23-4-169]\]. Primary CH is usually caused by abnormal thyroid gland development, but 10%--15% of cases are caused by genetic defects in proteins involved in individual stages of thyroid hormone biosynthesis (thyroid dyshormonogenesis) \[[@b4-apem-2018-23-4-169]\]. The thyroid hormone biosynthesis pathway is well-characterized, including seven genes \[[@b5-apem-2018-23-4-169]\]. Thyroid dyshormonogenesis has been understood to be a biallelic disease, but there are reports of oligogenic and monoallelic cases \[[@b6-apem-2018-23-4-169]\]. Since phenotypes vary even among individuals with similar mutations, several factors determine disease severity \[[@b7-apem-2018-23-4-169]\]. CH can be categorized into permanent CH, which requires lifetime thyroid hormone replacement, and transient CH, characterized by a temporary thyroid hormone deficiency for the first few months or years after birth and later recovery of normal thyroid function \[[@b4-apem-2018-23-4-169]\].

Primary CH can be diagnosed biochemically by elevated serum thyroid stimulating hormone (TSH) and decreased thyroxine (T4) and triiodothyronine (T3) levels. For etiological diagnosis, thyroid ultrasonography, thyroid scintigraphy using ^99m^pertechnetate or ^123^I, or the perchlorate discharge test can be used \[[@b8-apem-2018-23-4-169]\].

In cases diagnosed as CH based on TSH, T4, and T3 values where an etiological diagnosis cannot be performed before starting levothyroxine (L-T4) replacement, it is recommended to stop L-T4 for a month at the age of 3 years and reevaluate the patient by biochemical tests and thyroid imaging \[[@b8-apem-2018-23-4-169]\]. However, the downside of thyroid scintigraphy and the perchlorate discharge test is that the patient is exposed to radiation. While thyroid scintigraphy is widely used to diagnose ectopic thyroid, the perchlorate discharge test is used relatively infrequently to differentiate the etiology of thyroid dyshormonogenesis. One reason is that the treatment for CH is always L-T4 replacement, irrespective of the cause. For the same reason, genetic diagnosis of thyroid dyshormonogenesis was not often conducted in the age of Sanger sequencing. Despite the lack of treatment implications, genetic diagnosis can provide insight into prognosis. Steady growth in the use of massively parallel sequencing (next-generation sequencing, NGS), including in Korea, where panel sequencing based on NGS (targeted exome sequencing) has been covered by insurance since 2017, we expect changes in the diagnostic approach to thyroid dyshormonogenesis.

Thus, we review the thyroid hormone biosynthesis pathway, followed by detailed summaries of genes in the pathway, including the frequencies and effects of mutations in these genes. Finally, we discuss the use of targeted exome sequencing for diagnosis.

Thyroid hormone biosynthesis
============================

The major substrates of thyroid hormone synthesis are iodine and tyrosine. The initial step in the thyroid hormone biosynthesis process is the binding of TSH to TSH receptors in the basolateral membrane of thyroid follicular cells, activating cyclic adenosine monophosphate \[[@b1-apem-2018-23-4-169]\]. Thyroid hormones are then synthesized in the thyroid gland in the following stages ([Fig. 1](#f1-apem-2018-23-4-169){ref-type="fig"}).

1. Thyroid iodide transport
---------------------------

Iodine (I) in food is absorbed in the form of iodide (I^-^) and travels to the thyroid gland in the boodstream. Iodide accumulates in thyroid follicular cells via sodium iodide symporter (NIS; SLC5A5) channels in the basolateral membrane of these cells \[[@b9-apem-2018-23-4-169]\]. NIS is an intrinsic transmembrane protein that actively transports iodide together with sodium. Ions such as perchlorate and pertechnetate are also transported to the thyroid gland by the same mechanisms and act as competitive inhibitors of iodide transport. Inside thyroid follicular cells, iodide rapidly diffuses to the apical membrane, where it is transported into colloid by pendrin (PDS; SLC26A4) channels \[[@b9-apem-2018-23-4-169]\].

2. Thyroglobulin synthesis
--------------------------

Thyroglobulin is a glycoprotein synthesized within the endoplasmic reticulum (ER) of thyroid follicular cells; it forms exocytotic vesicles that migrate into the colloid via the apical membrane \[[@b10-apem-2018-23-4-169],[@b11-apem-2018-23-4-169]\]. The tyrosine residues on thyroglobulin are used as substrates for the synthesis of thyroid hormone \[[@b11-apem-2018-23-4-169]\].

3. Oxidation and organification
-------------------------------

Iodide that has been transported to colloid undergoes oxidation to iodine, which is then covalently bound (organified) to the tyrosine residues in thyroglobulin to form monoiodotyrosine (MIT) and diiodotyrosine (DIT) \[[@b10-apem-2018-23-4-169]\]. The oxidation of iodide is catalyzed by thyroid peroxidase (TPO), and hydrogen peroxide (H~2~O~2~) is required for this reaction \[[@b12-apem-2018-23-4-169]\].

4. H~2~O~2~ generation
----------------------

H~2~O~2~ required for the TPO-catalyzed reaction is produced by nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase complexes located on the apical membrane \[[@b13-apem-2018-23-4-169],[@b14-apem-2018-23-4-169]\]. The oxidases producing H~2~O~2~ in the thyroid gland are dual oxidase 1 (DUOX1) and dual oxidase 2 (DUOX2); the latter is more important for maintaining normal thyroid function \[[@b1-apem-2018-23-4-169]\]. Dual oxidase maturation factor (DUOXA) translocates DUOX from the ER to the plasma membrane, and DUOXA2 dysfunction causes thyroid dyshormonogenesis \[[@b15-apem-2018-23-4-169]\].

5. Coupling of iodotyrosyl residues of thyroglobulin
----------------------------------------------------

In thyroglobulin molecules, T4 forms when two DITs combine and T3 forms when one MIT combines with one DIT. These reactions are also catalyzed by TPO \[[@b10-apem-2018-23-4-169]\].

6. Endocytosis of colloid and hormone release
---------------------------------------------

To secrete T4 and T3, thyroglobulin is endocytosed by thyroid follicular cells in the form of colloid droplets. The droplets bind to lysosomes where they undergo hydrolysis, resulting in the release of T4, T3, DIT, and MIT. T4 and T3 are then secreted into the blood.

7. Recycling of iodide
----------------------

DIT and MIT released following the hydrolysis of thyroglobulin are converted into free iodide and tyrosine by iodotyrosine deiodinase (IYD) (also known as iodotyrosine dehalogenase 1 (DEHAL1)), and the free iodide and tyrosine are then utilized inside of follicular cells \[[@b16-apem-2018-23-4-169]\].

The genetic causes of thyroid dyshormonogenesis are summarized in [Table 1](#t1-apem-2018-23-4-169){ref-type="table"} and in the following sections, which describe the roles of genes involved in the thyroid hormone biosynthesis pathway.

*NIS (SLC5A5)* mutations: basolateral iodide transport defect
=============================================================

NIS is a 13-transmembrane domain glycoprotein that mediates active iodide transport in various tissues, such as the thyroid gland, salivary glands, stomach, lactating breasts, and small intestine \[[@b17-apem-2018-23-4-169]\]. NIS located on the basolateral membrane of the thyroid follicular cells actively transport one I- ion for every two Na^+^ ions, using the sodium gradient produced by Na^+^/K^+^ ATPase \[[@b17-apem-2018-23-4-169]\].

The first case of CH caused by an iodide transport defect was described by Stanbury and Chapman in 1960 \[[@b18-apem-2018-23-4-169]\]. Fujiwara et al. \[[@b19-apem-2018-23-4-169]\] first elucidated the molecular basis for an iodide transport defect, i.e., a mutation in the *SLC5A5* gene. Since then, 15 mutations in *SLC5A5* have been reported in the Human Gene Mutation Database (HGMD), and these show autosomal recessive inheritance \[[@b20-apem-2018-23-4-169]\]. Clinically, these mutations cause hypothyroidism accompanied by goiter with eutopic thyroid on thyroid ultrasonography but show low or absent radioactive iodine uptake (RAIU) in thyroid scintigraphy \[[@b21-apem-2018-23-4-169]\]. In addition, the stomach and salivary glands, which also contain NIS, are unable to uptake radioiodine \[[@b5-apem-2018-23-4-169]\]. Variation in the extent of hypothyroidism is related to a residual *in vitro* activity of mutant NIS \[[@b22-apem-2018-23-4-169]\]. In patients with residual NIS activity, thyroid function is improved by iodide supplementation; accordingly, iodide supplementation alone or in combination with L-T4 replacement is an appropriate treatment approach \[[@b1-apem-2018-23-4-169]\]. In Korea, there are no reported cases of CH caused by a mutation in *SLC5A5* to date.

*PDS (SLC26A4)* mutations: apical iodide transport defect (Pendred syndrome)
============================================================================

Pendrin is a multifunctional anion exchanger expressed in the thyroid, inner ear, and kidney; in the thyroid, pendrin is located in the apical membrane of follicular cells and is thought to mediate apical iodide transport \[[@b23-apem-2018-23-4-169]\]. Pendrin is encoded by the SLC26A4 gene. Homozygous or compound heterozygous mutations in *SLC26A4* can cause Pendred syndrome \[[@b24-apem-2018-23-4-169]\], an autosomal recessive disease characterized by congenital bilateral sensorineural deafness and goiter and the most common cause of syndromic deafness \[[@b24-apem-2018-23-4-169]\]. To date, 539 *SLC26A4* mutations have been reported in the HGMD \[[@b20-apem-2018-23-4-169]\]. However, not all mutations in *SLC26A4* cause Pendred syndrome and approximately half of mutations cause deafness with normal thyroid function (nonsyndromic hearing loss with familial enlarged vestibular aqueduct or DFNB4) \[[@b1-apem-2018-23-4-169]\].

Hypothyroidism in Pendred syndrome is usually mild and often undetected in neonatal screening \[[@b25-apem-2018-23-4-169]\]. Goiter typically develops in childhood, but cases of congenital goiter have also been reported \[[@b26-apem-2018-23-4-169]\]. Iodide intake affects the thyroid phenotype, and congenital goiter is more common in iodine-deficient areas \[[@b5-apem-2018-23-4-169]\]. Although the perchlorate discharge test is usually positive, some patients show a normal test \[[@b27-apem-2018-23-4-169]\].

*TG* mutations: thyroglobulin synthesis defect
==============================================

Thyroglobulin is the most abundantly expressed large homodimeric glycoprotein in the thyroid and acts as a matrix for the synthesis of thyroid hormone \[[@b11-apem-2018-23-4-169]\]. Thyroglobulin defects caused by mutations in *TG* are autosomal recessive and show a diverse clinical spectrum, ranging from a euthyroid state to severe hypothyroidism \[[@b11-apem-2018-23-4-169]\]. Most patients show congenital goiter or develop goiter soon after birth. There is a characteristic decrease in the serum thyroglobulin level \[[@b28-apem-2018-23-4-169]\]. Thyroglobulin defects caused by *TG* mutations lead to CH due to either quantitative or functional deficiency \[[@b29-apem-2018-23-4-169],[@b30-apem-2018-23-4-169]\]. Functional deficiency can be caused by a thyroglobulin transport defect, where thyroglobulin accumulates in the ER and is not secreted into follicles, or by structural abnormalities in thyroglobulin leading to the reduced coupling and synthesis of MIT and DIT \[[@b30-apem-2018-23-4-169]\]. The first *TG* mutation was reported in 1991 \[[@b29-apem-2018-23-4-169]\], and 133 mutations have been reported in the HGMD to date \[[@b20-apem-2018-23-4-169]\].

*TPO* mutations: organification and coupling defect
===================================================

TPO is a membrane-bound heme protein located in the apical membrane of thyroid follicular cells, and is involved in the coupling and tyrosyl iodination of thyroglobulin \[[@b10-apem-2018-23-4-169]\]. A biallelic mutation in *TPO* was first reported in 1992 \[[@b31-apem-2018-23-4-169]\], and currently 125 different mutations in *TPO* are reported in the HGMD \[[@b20-apem-2018-23-4-169]\]. Most patients show severe hypothyroidism and congenital goiter \[[@b5-apem-2018-23-4-169]\]. High RAIU is observed in scintigraphy, serum thyroglobulin level is elevated, and the perchlorate discharge test is positive \[[@b32-apem-2018-23-4-169]\]. CH caused by *TPO* mutations shows autosomal recessive inheritance, but approximately 20% of patients possess only a single TPO mutation \[[@b1-apem-2018-23-4-169]\]. This can be explained by unidentified mutations in intronic or regulatory regions, monoallelic expression of mutant *TPO* \[[@b33-apem-2018-23-4-169]\], or cosegregation of mutant and null *TPO* alleles \[[@b34-apem-2018-23-4-169]\].

*DUOX2* and *DUOXA2* mutations: H~2~O~2~ generation defect
==========================================================

DUOX2 produces H~2~O~2~, which is required for TPO-catalyzed reactions, while DUOXA2 acts as a maturation factor for DUOX2 \[[@b1-apem-2018-23-4-169],[@b35-apem-2018-23-4-169]\].

CH caused by mutations in *DUOX2* was first reported in 2002 and shows both autosomal recessive and autosomal dominant inheritance \[[@b36-apem-2018-23-4-169]\]. It was initially claimed that biallelic inactivating mutations cause severe and permanent CH, while monoallelic mutations are associated with mild and transient hypothyroidism \[[@b36-apem-2018-23-4-169]\]. However, later studies have reported biallelic mutations in *DUOX2* in patients with transient hypothyroidism \[[@b37-apem-2018-23-4-169],[@b38-apem-2018-23-4-169]\] and have shown that monoallelic mutations can cause permanent CH \[[@b7-apem-2018-23-4-169],[@b39-apem-2018-23-4-169]\]. In a sequence analysis of *DUOX2, TPO, TSHR*, and *TG* in 43 patients with CH with eutopic thyroid gland in Korea, 23 patients (53.5%) had a sequence variant in *DUOX2*, indicating that *DUOX2* mutations are a frequent genetic cause of thyroid dyshormonogenesis in Koreans \[[@b40-apem-2018-23-4-169]\]. Monoallelic and biallelic mutations can both cause transient or permanent CH, and there is no correlation between the phenotype and the number of mutant alleles \[[@b40-apem-2018-23-4-169]\]. Sequence analysis of *DUOX2*, *DUOXA2*, and *TPO* in 48 Japanese patients was performed, and *DUOX2* mutations showed the highest frequency \[[@b41-apem-2018-23-4-169]\]. Currently, 159 different mutations in *DUOX2* are reported in the HGMD \[[@b20-apem-2018-23-4-169]\].

CH caused by *DUOX2* mutations is characterized by goiter, elevated TG, low free T4, and significantly elevated TSH, and most patients show PIOD in the perchlorate discharge test \[[@b7-apem-2018-23-4-169]\]. In patients with a DUOX2 defect, an excessive amount of dietary iodide facilitates better use of the H~2~O~2~ provided by DUOX1, indicating the potential for some compensation \[[@b42-apem-2018-23-4-169]\].

CH caused by *DUOXA2* mutations was first detected in 2008 in patients who showed partial iodide organification defect (PIOD) but lacked mutations in *TPO* or *DUOX2* \[[@b15-apem-2018-23-4-169]\]. The inheritance pattern is autosomal recessive, and 17 mutations have been reported in the HGMD \[[@b20-apem-2018-23-4-169]\]. However, in 2015, a monoallelic *DUOXA2* mutation associated with transient CH was reported, emphasizing the need for further research \[[@b43-apem-2018-23-4-169]\].

*IYD* mutations: iodide recycling defect
========================================

IYD is a transmembrane protein located in the apical membrane of thyroid follicular cells, and releases free iodide from MIT and DIT, allowing it to be used again in thyroid hormone synthesis \[[@b44-apem-2018-23-4-169]\]. CH caused by *IYD* mutations was first reported in 2008 \[[@b45-apem-2018-23-4-169]\], and four mutations are currently reported in the HGMD \[[@b20-apem-2018-23-4-169]\]. Patients are characterized by normal thyroid function in neonatal screening, followed by the development of goiter and excessive urinary secretion of DIT and MIT in infancy and childhood \[[@b45-apem-2018-23-4-169]\]. Although inheritance is autosomal recessive, one heterozygous carrier developed goiter and hypothyroidism during follow-up monitoring \[[@b46-apem-2018-23-4-169]\].

Thyroid imaging for the diagnosis of thyroid dyshormonogenesis
==============================================================

Thyroid ultrasonography, thyroid scintigraphy or perchlorate discharge test can be used for etiological diagnosis \[[@b8-apem-2018-23-4-169]\]. In thyroid dyshormonogenesis, thyroid ultrasonography shows eutopic thyroid and depending on the severity of hypothyroidism, the thyroid size may be normal or large. Thyroid scintigraphy using ^99m^pertechnetate or ^123^I reflects NIS expression, because both ^99m^pertechnetate and ^123^I are captured by NIS \[[@b47-apem-2018-23-4-169]\]. When thyroid scintigraphy shows low or absent RAIU, this finding is suggestive of basolateral iodide transport defect (*NIS* mutations). Normal or high RAIU is suggestive of one of the dyshormonogenesis beyond iodide trapping \[[@b5-apem-2018-23-4-169],[@b21-apem-2018-23-4-169]\]. In neonates and children, ^99m^pertechnetate is preferred for thyroid scintigraphy, since it results in less radiation exposure \[[@b47-apem-2018-23-4-169]\]. However, ^99m^pertechnetate is not organified. When thyroid scintigraphy shows normal or high RAIU, ^123^I scintigraphy with perchlorate discharge test can detect iodide organification defects \[[@b47-apem-2018-23-4-169]\]. In the perchlorate discharge test, first radioactive iodine is administered, sufficient time is allowed to pass so that the radioactive iodine is captured by the thyroid and then, perchlorate is administered orally. The perchlorate displaces nonorganified iodide from the thyroid. The perchlorate discharge test is considered positive (abnormal) if there is an abnormally rapid loss of radioactive iodine from the thyroid \[[@b48-apem-2018-23-4-169]\]. The release of ≥90% is defined as a total iodide organification defect (TIOD), while the release of 10%--90% is defined as a PIOD \[[@b49-apem-2018-23-4-169]\]. Homozygous or compound heterozygous *TPO* mutations lead to TIOD, whereas heterozygous *TPO* mutations show PIOD \[[@b49-apem-2018-23-4-169]\]. *DUOX2* mutations also lead to TIOD or PIOD \[[@b5-apem-2018-23-4-169]\]. *DUOXA2* mutations usually show PIOD \[[@b5-apem-2018-23-4-169]\]. Furthermore, PDS mutations show a positive perchlorate discharge test \[[@b49-apem-2018-23-4-169]\]. *TG* or *IYD* mutations usually show a negative perchlorate discharge test \[[@b5-apem-2018-23-4-169]\]. Although perchlorate discharge test is useful for diagnosing thyroid dyshormonogenesis, it may not suggest the specific underlying molecular mechanism.

NGS for the diagnosis of CH
===========================

Increased molecular diagnosis of primary CH has led to the discovery of various genetic causes and inheritance patterns for both thyroid dyshormonogenesis and thyroid dysgenesis. Most previous studies have focused on one or several genes that cause CH, and the study populations have usually been limited to subgroups of CH. Recently, in China, targeted exome sequencing has been used to evaluate 21 candidate genes known to cause CH (thyroid dysgenesis, thyroid dyshormonogenesis, and resistance to thyroid hormone) in 110 patients with primary CH \[[@b50-apem-2018-23-4-169]\]. Thyroid dyshormonogenesis is a more common cause of CH than thyroid dysgenesis in China, and mutations are most commonly observed in the *DUOX2* gene \[[@b50-apem-2018-23-4-169]\].

From a practical perspective, thyroid dysgenesis can be easily diagnosed by thyroid imaging without knowing the genetic cause. The incidence of CH detected by neonatal screening has increased, with a particular increase in the incidence of CH with eutopic thyroid. A large proportion of these cases are expected to be thyroid dyshormonogenesis. Thyroid dyshormonogenesis can cause permanent or transient CH depending on the genetic cause, and often goes undiagnosed in neonatal screening and does not show symptoms until later. The genetic diagnosis of thyroid dyshormonogenesis using targeted exome sequencing could provide great benefits not only to current patients but also in genetic counselling for subsequent generations.

Conclusions
===========

Thyroid dyshormonogenesis could be a more common cause of CH than was previously understood. Thyroid dyshormonogenesis can cause permanent or transient CH, depending on the genetic cause, and shows both autosomal recessive and autosomal dominant inheritance patterns. Targeted exome sequencing of 7 causative genes for thyroid dyshormonogenesis could improve the prediction of prognoses for current patients and could be useful for genetic counselling for subsequent generations.
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###### 

Causes of thyroid dyshormonogenesis

  Substance                          Gene              Cytogenetic location   Phenotype MIM number   Inheritance
  ---------------------------------- ----------------- ---------------------- ---------------------- -------------
  Sodium iodide symporter            *SLC5A5 (NIS)*    19p13.11               274400                 AR
  Pendrin                            *SLC26A4 (PDS)*   7q22.3                 274600                 AR
  Thyroglobulin                      *TG*              8q24.22                274700                 AR
  Thyroid peroxidase                 *TPO*             2p25.3                 274500                 AR
  Dual oxidase 2                     *DUOX2*           15q21.1                607200                 AR, AD
  Dual oxidase maturation factor 2   *DUOXA2*          15q21.1                274900                 AR, (AD?)
  Iodotyrosine deiodinase            *IYD (DEHAL1)*    6q25.1                 274800                 AR, (AD?)

AR, autosomal recessive; AD, autosomal dominant.
